<DOC>
	<DOC>NCT00719225</DOC>
	<brief_summary>To make belatacept available for recipients of a renal allograft who are currently intolerant to or have contraindications to CNIs and/or m-TOR inhibitors and are either: - unable to construct an adequate immunosuppression regimen due to non-renal toxicity / contraindication (and withdrawing the causative agent would lead to renal graft loss) OR - at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other options for renal replacement therapy</brief_summary>
	<brief_title>A Belatacept Compassionate Use Study for Patients With a Kidney Transplant</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>Please call 8003989157 for information on this study Men and women of age 18 years or older inclusive Recipient of a renal allograft for at least ≥ 2 months EBV positive Unable to tolerate a suitable immunosuppression regimen to prevent acute allograft rejection, due to: Extrarenal toxicity related to CNIs and/or mTOR inhibitors that is refractory to medical management (eg, uncontrolled seizures) Contraindication to CNIs and/or mTOR inhibitors OR At imminent risk of losing allograft kidney due to nephrotoxicity Renal failure: ≥ Stage 4 on KDOQI Scale (GFR 15 29 cc/min) And no other renal replacement therapy Subjects must be receiving the maintenance immunosuppressants MMF, MPA, or AZA Any significant infection, extrarenal solid organ (heart, liver, pancreas) or cell (islet, bone marrow, stem cell) transplants, with an unresolved episode of AR within the last 6 weeks EBV negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>